BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Gut Microbiome Health Tech Innovator, Ixcela Launches Virtual Clinic to Ease Cancer Symptoms After Landmark Roper St. Francis Healthcare Pilot

  October 2, 2024

   · 

  5 min read
• Press Releases

  First U.S. Women Successfully Receive Breast Augmentation with New FDA Approved Motiva Implants

  October 2, 2024

   · 

  7 min read
• Press Releases

  ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

  October 2, 2024

   · 

  7 min read
• Press Releases

  Forge Biologics Announces the FUEL™ AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production

  October 2, 2024

   · 

  3 min read
• Press Releases

  Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

  October 2, 2024

   · 

  3 min read
• Press Releases

  Xcell Biosciences Expands AmplifyBio Collaboration with Unique Cell and Gene Therapy Manufacturing Capabilities

  October 2, 2024

   · 

  3 min read
• Press Releases

  Mithradote Bio Closes Oversubscribed $1 Million Seed Round for Development of the First Self-Administered Antidote Against Drink Spiking

  October 2, 2024

   · 

  3 min read
• Press Releases

  Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

  October 2, 2024

   · 

  5 min read
• Press Releases

  Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

  October 2, 2024

   · 

  6 min read
• Drug Development

  ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer

  October 2, 2024

   · 

  15 min read